SCHEMBL25399646

SCHEMBL25399646

FC(F)(F)ON1CCNCC1

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 1/20 0.33
ALDH1A1 P00352 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22401188 0.75
SCHEMBL557226 0.74
SCHEMBL28345417 0.70 OPRD1 (0.31)
SCHEMBL6099999 0.68 MEN1 (0.35)
SCHEMBL11564684 0.67 HIF1A (0.33) ADRB1ALDH1A1LMNA
SCHEMBL3317716 0.67 CXCR4 (0.32)
SCHEMBL2728754 0.66 CA2 (0.34)
SCHEMBL3324302 0.66 CXCR4 (0.32)
Hydrochloric Acid SCHEMBL27445441 0.65 ALDH1A1 (0.35) ALDH1A1LMNA
SCHEMBL2931839 0.63

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12502386-B2 Nitrogen-containing heterocyclic compound and use thereof Shanghai Shijiang Biotechnology Co., Ltd. (CN) 2025-12-23 US claimed
US-20250197389-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND SHANGHAI SHIJIANG BIOTECHNOLOGY CO., LTD (CN) 2025-06-19 US claimed
US-20250197415-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF SHANGHAI SHIJIANG BIOTECHNOLOGY CO., LTD (CN) 2025-06-19 US claimed
US-12502386-B2 Nitrogen-containing heterocyclic compound and use thereof Shanghai Shijiang Biotechnology Co., Ltd. (CN) 2025-12-23 US disclosed
US-20250197389-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND SHANGHAI SHIJIANG BIOTECHNOLOGY CO., LTD (CN) 2025-06-19 US disclosed
US-20250197415-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF SHANGHAI SHIJIANG BIOTECHNOLOGY CO., LTD (CN) 2025-06-19 US disclosed
EP-4495116-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Shanghai Shijiang Biotechnology Co., Ltd (CN) 2025-01-22 EP disclosed
EP-4495117-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF Shanghai Shijiang Biotechnology Co., Ltd (CN) 2025-01-22 EP disclosed
CN-117813305-A Nitrogen-containing heterocyclic compound and application thereof 南京施江医药科技有限公司 2024-04-02 CN disclosed
CN-117529480-A Nitrogen-containing heterocyclic compound 南京施江医药科技有限公司 2024-02-06 CN disclosed
WO-2023174381-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF 南京施江医药科技有限公司 2023-09-21 WO disclosed
WO-2023174378-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND 南京施江医药科技有限公司 2023-09-21 WO disclosed
CN-104955824-B It is used as the aminopyrimidine compounds of the inhibitor of the EGFR mutant containing T790M 豪夫迈·罗氏有限公司 2017-09-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250197389-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND PPIF, PIN1, NME4 ADRB1 4671/4885ALDH1A1 3141/4885LMNA 2301/4885
US-20250197415-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE THEREOF UHRF1, NNMT, EHMT1 ADRB1 3508/4885ALDH1A1 956/4885LMNA 4217/4885
US-12502386-B2 Nitrogen-containing heterocyclic compound and use thereof UHRF1, NNMT, EHMT1 ADRB1 3508/4885ALDH1A1 956/4885LMNA 4217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.